Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 11/20 | 0.64 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527428 | 0.90 | CYP17A1 (0.67) | CYP17A1PRMT6PTGS1PTGS2JAK1 | |
| SCHEMBL526869 | 0.83 | CYP17A1 (0.70) | CYP17A1PTGS1PTGS2 | |
| SCHEMBL527268 | 0.82 | PRMT6 (0.58) | CYP17A1PRMT6PTGS1PTGS2ABL1 | |
| SCHEMBL15746951 | 0.79 | CYP17A1 (1.00) | CYP17A1PRMT6 | |
| SCHEMBL526391 | 0.72 | CYP17A1 (0.78) | CYP17A1PTGS1PTGS2 | |
| SCHEMBL527762 | 0.71 | CYP17A1 (0.48) | CYP17A1ABL1 | |
| SCHEMBL526628 | 0.70 | CYP17A1 (0.59) | CYP17A1PTGS1PTGS2 | |
| SCHEMBL527415 | 0.70 | CYP17A1 (0.59) | CYP17A1PTGS1PTGS2 | |
| SCHEMBL18112987 | 0.70 | BRPF1 (0.45) | CYP17A1BRPF1 | |
| SCHEMBL526755 | 0.69 | CYP17A1 (0.76) | CYP17A1PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012015723-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-02 | — | — | WO | disclosed |